(一)默沙东,K药单药,二线治疗黑色素瘤,ORR=17.5% keynote151研究,是一项开放标签、非随机、多中心,单臂的Ib期临床。 中国🇨🇳103例患者,中位年龄为52岁,37.9%患肢端黑色素瘤,14.6%患粘膜黑色素瘤,39.8%患非肢端皮肤型黑色素瘤,BRAF突变占19.4%,PD-L1表达阳性51.5%,68.9%为一线化疗后。全组的客观缓解率...
This year as BigSpeak turns 30, we also mark the one hundred year anniversary of the creation of the microphone. Exactly one hundred years ago in 1925, musicianArt Gillhamstepped into a recording studio to test run an exciting piece of cutting-edge tech: the microphone. This trial resulted ...
KEYNOTE-024:完成两年治疗疗程患者的分析结果 KEYNOTE-024 是第一个报道晚期 NSCLC 一线免疫治疗 5 年疗效的 III 期研究,经过 5 年随访继续支持了帕博利珠单抗是 PD-L1 TPS ≥ 50% 晚期 NSCLC 患者的有效一线治疗方案。提示在伴随诊断...